Protein S: A multifunctional anticoagulant vitamin K-dependent protein at the crossroads of coagulation, inflammation, angiogenesis, and cancer

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 3, 2013, Pages 637-654

  Suleiman, Lutfi ^a   Négrier, Claude ^a   Boukerche, Habib ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

Angiogenesis; Apoptosis; Coagulation; Inflammation; Metastasis; Protein S; Protein tyrosine kinase receptors; Signal transduction

Indexed keywords

PROTEIN S; TYROSINE KINASE RECEPTOR;

ANGIOGENESIS; ANTICOAGULATION; ATHEROSCLEROSIS; BLOOD CLOTTING; CANCER GROWTH; CELL FUNCTION; CELL PHAGOCYTOSIS; CELL SURVIVAL; ENZYME REGULATION; GENE; HUMAN; INFLAMMATION; INNATE IMMUNITY; METASTASIS; NEOPLASM; NONHUMAN; PROS1 GENE; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION;

ANGIOGENESIS; APOPTOSIS; COAGULATION; INFLAMMATION; METASTASIS; PROTEIN S; PROTEIN TYROSINE KINASE RECEPTORS; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD COAGULATION; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; PROMOTER REGIONS, GENETIC; PROTEIN S; VITAMIN K;

EID: 84888304601     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.07.004     Document Type: Review

References (217)

1. Di Scipio R.G., Hermodson M.A., Yates S.G., Davie E.W. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry 1977, 16:698-706.
2. Watkins P.C., Eddy R., Fukushima Y., et al. The gene for protein S maps near the centromere of human chromosome 3. Blood 1988, 71:238-241.
3. Schmidel D.K., Tatro A.V., Phelps L.G., Tomczak J.A., Long G.L. Organization of the human protein S genes. Biochemistry 1990, 29:7845-7852.
4. Walker F.J. Regulation of activated protein C by a new protein: a possible function for bovine protein S. Journal of Biological Chemistry 1980, 255:5521-5524.
5. Walker F.J., Chavin S.I., Fay P.J. Inactivation of factor VIII by activated protein C and protein S. Archives of Biochemistry and Biophysics 1987, 252:322-328.
6. Rosing J., Hoekema L., Nicolaes G.A., et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. Journal of Biological Chemistry 1995, 270:27852-27858.
7. O'Brien L.M., Mastri M., Fay P.J. Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase. Blood 2000, 95:1714-1720.
8. Hackeng T.M., Sere K.M., Tans G., et al. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proceeding of the National Academy of Sciences of the United States of America 2006, 103:3106-3111.
9. Ndonwi M., Broze G. Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. Journal of Thrombosis and Haemostasis 2008, 6:1044-1046.
10. Comp P.C., Esmon C.T. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. The New England Journal of Medicine 1984, 311:1525-1528.
11. Gandrille S., Borgel D., Sala N., et al. Protein S deficiency: a database of mutations-summary of the first update. Thrombosis and Haemostasis 2000, 84:918.
12. Mahasandana C., Veerakul G., Tanphaichitr V.S., et al. Homozygous protein S deficiency: 7-year follow-up. Thrombosis and Haemostasis 1996, 76:1122.
13. Dahlback B. Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thrombosis and Haemostasis 1991, 66:49-61.
14. Griffin J.H., Gruber A., Fernandez J.A. Reevaluation of total, free, and bound protein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin. Blood 1992, 79:3203-3211.
15. Nicolaes G.A., Tans G., Thomassen M.C., et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. ournal of Biological Chemistry 1995, 270:21158-21166.
16. Dahlback B. Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. Journal of Biological Chemistry 1986, 261:12022-12027.
17. Maurissen L.F., Thomassen M.C., Nicolaes G.A., et al. Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation. Blood 2008, 111:3034-3041.
18. Lemke G., Rothlin C.V. Immunobiology of the TAM receptors. Nature Reviews Immunology 2008, 8:327-336.
19. Rothlin C.V., Ghosh S., Zuniga E.I., et al. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007, 131:1124-1136.
20. Anderson H.A., Maylock C.A., Williams J.A., et al. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nature Immunology 2003, 4:87-91.
21. Burstyn-Cohen T., Heeb M.J., Lemke G. Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. Journal of Clinical Investigation 2009, 119:2942-2953.
22. Dahlback B. Blood coagulation. Lancet 2000, 355:1627-1632.
23. Nicolaes G.A., Dahlback B. Factor V and thrombotic disease: description of a janus-faced protein. Arteriosclerosis, Thrombosis, Vascular Biology 2002, 22:530-538.
24. Walker F.J. Protein S and the regulation of activated protein C. Seminars in Thrombosis and Hemostasis 1984, 10:131-138.
25. Furie B., Bouchard B.A., Furie B.C. Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood 1999, 93:1798-1808.
26. Stenflo J. Contributions of Gla and EGF-like domains to the function of vitamin K-dependent coagulation factors. Critical Reviews in Eukaryotic Gene Expression 1999, 9:59-88.
27. Walker F.J. Regulation of vitamin K-dependent protein S. Inactivation by thrombin. Journal of Biological Chemistry 1984, 259:10335-10339.
28. Dahlback B., Lundwall A., Stenflo J. Localization of thrombin cleavage sites in the amino-terminal region of bovine protein S. Journal of Biological Chemistry 1986, 261:5111-5115.
29. Long G.L., Lu D., Xie R.L., et al. Human protein S cleavage and inactivation by coagulation factor Xa. Journal of Biological Chemistry 1998, 273:11521-11526.
30. Giri T.K., Villoutreix B.O., Wallqvist A., et al. Topological studies of the amino terminal modules of vitamin K-dependent protein S using monoclonal antibody epitope mapping and molecular modeling. Thrombosis and Haemostasis 1998, 80:798-804.
31. Dahlback B., Hildebrand B., Malm J. Characterization of functionally important domains in human vitamin K-dependent protein S using monoclonal antibodies. Journal of Biological Chemistry 1990, 265:8127-8135.
32. Stenberg Y., Linse S., Drakenberg T., et al. The high affinity calcium-binding sites in the epidermal growth factor module region of vitamin K-dependent protein S. Journal of Biological Chemistry 1997, 272:23255-23260.
33. Villoutreix B.O., Garcia de Frutos P., Lovenklev M., et al. SHBG region of the anticoagulant cofactor protein S: secondary structure prediction, circular dichroism spectroscopy, and analysis of naturally occurring mutations. Proteins 1997, 29:478-491.
34. Lu D., Xie R.L., Rydzewski A., et al. The effect of N-linked glycosylation on molecular weight, thrombin cleavage, and functional activity of human protein S. Thrombosis and Haemostasis 1997, 77:1156-1163.
35. Giri T.K., Yamazaki T., Sala N., et al. Deficient APC-cofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors. Blood 2000, 96:523-531.
36. 2+-Binding EGF3-4 pair from vitamin K-dependent protein S: identification of an unusual fold in EGF3. Biochemistry 2005, 44:8782-8789.
37. Fuentes-Prior P., Iwanaga Y., Huber R., et al. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature 2000, 404:518-525.
38. Hambleton S., Valeyev N.V., Muranyi A., et al. Structural and functional properties of the human notch-1 ligand binding region. Structure 2004, 12:2173-2183.
39. Sasaki T., Knyazev P.G., Cheburkin Y., et al. Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6: receptor tyrosine kinase activation by laminin G-like domains. Journal of Biological Chemistry 2002, 277:44164-44170.
40. Sasaki T., Knyazev P.G., Clout N.J., et al. Structural basis for Gas6-Axl signalling. The EMBO Journal 2006, 25:80-87.
41. Hughes Q., Watson M., Cole V., et al. Upregulation of protein S by progestins. Journal of Thrombosis and Haemostasis 2007, 5:2243-2249.
42. de Wolf C.J., Cupers R.M., Bertina R.M., et al. The constitutive expression of anticoagulant protein S is regulated through multiple binding sites for Sp1 and Sp3 transcription factors in the protein S gene promoter. Journal of Biological Chemistry 2006, 281:17635-17643.
43. Tatewaki H., Tsuda H., Kanaji T., et al. Characterization of the human protein S gene promoter: a possible role of transcription factors Sp1 and HNF3 in liver. Thrombosis and Haemostasis 2003, 90:1029-1039.
44. Davis W., Chen Z.J., Ile K.E., et al. Reciprocal regulation of expression of the human adenosine 5'-triphosphate binding cassette, sub-family A, transporter 2 (ABCA2) promoter by the early growth response-1 (EGR-1) and Sp-family transcription factors. Nucleic Acids Research 2003, 31:1097-1107.
45. Sankpal U.T., Goodison S., Abdelrahim M., et al. Targeting Sp1 transcription factors in prostate cancer therapy. Medicinal Chemistry 2011, 7:518-525.
46. Sanda N., Fujimori Y., Kashiwagi T., et al. An Sp1 binding site mutation of the PROS1 promoter in a patient with protein S deficiency. British Journal of Haematology 2007, 138:663-665.
47. Suzuki A., Sanda N., Miyawaki Y., et al. Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. Journal of Biological Chemistry 2010, 285:13444-13453.
48. Gruber C.J., Tschugguel W., Schneeberger C., et al. Production and actions of estrogens. The New England Journal of Medicine 2002, 346:340-352.
49. Lidegaard O., Lokkegaard E., Svendsen A.L., et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. British Medical Journal 2009, 339:b2890.
50. Blanco-Molina A., Monreal M. Venous thromboembolism in women taking hormonal contraceptives. Expert Review of Cardiovascular Therapy 2010, 8:211-215.
51. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Research and Therapy 2006, 8(Suppl 2):S3.
52. Sriuranpong V., Park J.I., Amornphimoltham P., et al. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Research 2003, 63:2948-2956.
53. Robinson D.R., Wu Y.M., Lin S.F. The protein tyrosine kinase family of the human genome. Oncogene 2000, 19:5548-5557.
54. O'Bryan J.P., Frye R.A., Cogswell P.C., et al. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Molecular and Cellular Biology 1991, 11:5016-5031.
55. Rescigno J., Mansukhani A., Basilico C. A putative receptor tyrosine kinase with unique structural topology. Oncogene 1991, 6:1909-1913.
56. Yamagata M., Sanes J.R., Weiner J.A. Synaptic adhesion molecules. Current Opinion in Cell Biology 2003, 15:621-632.
57. Seitz H.M., Camenisch T.D., Lemke G., et al. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. Journal of Immunology 2007, 178:5635-5642.
58. Lu Q., Gore M., Zhang Q., et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 1999, 398:723-728.
59. Lu Q., Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001, 293:306-311.
60. Prasad D., Rothlin C.V., Burrola P., et al. TAM receptor function in the retinal pigment epithelium. Molecular and Cellular Neurosciences 2006, 33:96-108.
61. Angelillo-Scherrer A., de Frutos P., Aparicio C., et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nature Medicine 2001, 7:215-221.
62. Angelillo-Scherrer A., Burnier L., Flores N., et al. Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. Journal of Clinical Investigation 2005, 115:237-246.
63. Gould W.R., Baxi S.M., Schroeder R., et al. Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses. Journal of Thrombosis and Haemostasis 2005, 3:733-741.
64. Angelillo-Scherrer A., Burnier L., Lambrechts D., et al. Role of Gas6 in erythropoiesis and anemia in mice. Journal of Clinical Investigation 2008, 118:583-596.
65. Linger R.M., Keating A.K., Earp H.S., et al. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Advances in Cancer Research 2008, 100:35-83.
66. Stitt T.N., Conn G., Gore M., et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 1995, 80:661-670.
67. Stenflo J., Lundwall A., Dahlback B. beta-Hydroxyasparagine in domains homologous to the epidermal growth factor precursor in vitamin K-dependent protein S. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:368-372.
68. Chen J., Carey K., Godowski P.J. Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene 1997, 14:2033-2039.
69. Godowski P.J., Mark M.R., Chen J., et al. Reevaluation of the roles of protein S and Gas6 as ligands for the receptor tyrosine kinase Rse/Tyro 3. Cell 1995, 82:355-358.
70. Mark M.R., Chen J., Hammonds R.G., et al. Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl. Journal of Biological Chemistry 1996, 271:9785-9789.
71. Nagata K., Ohashi K., Nakano T., et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. Journal of Biological Chemistry 1996, 271:30022-30027.
72. Saller F., Brisset A.C., Tchaikovski S.N., et al. Generation and phenotypic analysis of protein S-deficient mice. Blood 2009, 114:2307-2314.
73. Tracey K.J. Reflex control of immunity. Nature Reviews Immunology 2009, 9:418-428.
74. deCathelineau A.M., Henson P.M. The final step in programmed cell death: phagocytes carry apoptotic cells to the grave. Essays in Biochemistry 2003, 39:105-117.
75. Wu Y., Singh S., Georgescu M.M., Birge R.B. A role for Mer tyrosine kinase in alphavbeta5 integrin-mediated phagocytosis of apoptotic cells. Journal of Cell Science 2005, 118:539-553.
76. Uehara H., Shacter E. Auto-oxidation and oligomerization of protein S on the apoptotic cell surface is required for Mer tyrosine kinase-mediated phagocytosis of apoptotic cells. Journal of Immunology 2008, 180:2522-2530.
77. McHenry C.L., Liu Y., Feng W., et al. MERTK arginine-844-cysteine in a patient with severe rod-cone dystrophy: loss of mutant protein function in transfected cells. Investigative Ophthalmology and Visual Science 2004, 45:1456-1463.
78. Thompson D.A., McHenry C.L., Li Y., et al. Retinal dystrophy due to paternal isodisomy for chromosome 1 or chromosome 2, with homoallelism for mutations in RPE65 or MERTK, respectively. American Journal of Human Genetics 2002, 70:224-229.
79. Camenisch T.D., Koller B.H., Earp H.S., et al. A novel receptor tyrosine kinase, Mer, inhibits TNF-alpha production and lipopolysaccharide-induced endotoxic shock. Journal of Immunology 1999, 162:3498-3503.
80. Scott R.S., McMahon E.J., Pop S.M., et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 2001, 411:207-211.
81. Cohen P.L., Caricchio R., Abraham V., et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. The Journal of Experimental Medicine 2002, 196:135-140.
82. Todt J.C., Hu B., Curtis J.L. The receptor tyrosine kinase MerTK activates phospholipase C gamma2 during recognition of apoptotic thymocytes by murine macrophages. Journal of Leukocyte Biology 2004, 75:705-713.
83. Nandrot E.F., Kim Y., Brodie S.E., et al. Loss of synchronized retinal phagocytosis and age-related blindness in mice lacking alphavbeta5 integrin. The Journal of Experimental Medicine 2004, 200:1539-1545.
84. Nakano T., Ishimoto Y., Kishino J., et al. Cell adhesion to phosphatidylserine mediated by a product of growth arrest-specific gene 6. Journal of Biological Chemistry 1997, 272:29411-29414.
85. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
86. Sabroe I., Parker L.C., Dower S.K., et al. The role of TLR activation in inflammation. The Journal of Pathology 2008, 214:126-135.
87. Arancibia S.A., Beltran C.J., Aguirre I.M., et al. Toll-like receptors are key participants in innate immune responses. Biological Research 2007, 40:97-112.
88. Berche P. Bacterial aggression. Annales Pharmaceutiques Françaises 2003, 61:270-275.
89. Wang J., Hu Y., Deng W.W., et al. Negative regulation of Toll-like receptor signaling pathway. Microbes and Infection 2009, 11:321-327.
90. Lemke G., Burstyn-Cohen T. TAM receptors and the clearance of apoptotic cells. Annals of the New York Academy of Sciences 2010, 1209:23-29.
91. Deng T., Zhang Y., Chen Q., et al. Toll-like receptor-mediated inhibition of Gas6 and ProS expression facilitates inflammatory cytokine production in mouse macrophages. Immunology 2012, 135:40-50.
92. Sen P., Wallet M.A., Yi Z., et al. Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells. Blood 2007, 109:653-660.
93. Keeling D.M., Campbell S.J., Mackie I.J., et al. Total and free protein S in systemic lupus erythematosus. Thrombosis Research 1990, 60:237-240.
94. Ginsberg J.S., Demers C., Brill-Edwards P., et al. Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus. The American Journal of Medicine 1995, 98:379-383.
95. Song K.S., Park Y.S., Kim H.K. Prevalence of anti-protein S antibodies in patients with systemic lupus erythematosus. Arthritis and Rheumatism 2000, 43:557-560.
96. Suh C.H., Hilliard B., Li S., et al. TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Research and Therapy 2010, 12:R146.
97. Kempton C.L., Bagby G., Collins J.F. Ulcerative colitis presenting as purpura fulminans. Inflammatory Bowel Diseases 2001, 7:319-322.
98. Aadland E., Odegaard O.R., Roseth A., et al. Free protein S deficiency in patients with chronic inflammatory bowel disease. Scandinavian Journal of Gastroenterology 1992, 27:957-960.
99. Stadnicki A., Bojko B., Myczkowska K., et al. Selected risk factors of thrombotic complications in patients with ulcerative colitis. Wiadomosci Lekarskie 2003, 56:341-347.
100. Miroux F., Arrive L., Monnier-Cholley L., et al. Thrombosis of the renal vein and hemorrhagic rectocolitis. Journal de Radiologie 1996, 77:671-673.
101. Koutroubakis I.E., Sfiridaki A., Mouzas I.A., et al. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. The American Journal of Gastroenterology 2000, 95:190-194.
102. Rodriguez G., Mago N., Rosa F. Role of inflammation in atherogenesis. Investigacion Clinica 2009, 50:109-129.
103. Morel D.W., Hessler J.R., Chisolm G.M. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. Journal of Lipid Research 1983, 24:1070-1076.
104. Rice-Evans C., Burdon R. Free radical-lipid interactions and their pathological consequences. Progress in Lipid Research 1993, 32:71-110.
105. Laberge M.A., Moore K.J., Freeman M.W. Atherosclerosis and innate immune signaling. Annals of Medicine 2005, 37:130-140.
106. Hurtado B., Abasolo N., Munoz X., et al. Association study between polymorphims in GAS6-TAM genes and carotid atherosclerosis. Thrombosis and Haemostasis 2010, 104:592-598.
107. Hurtado B., Munoz X., Recarte-Pelz P., et al. Expression of the vitamin K-dependent proteins GAS6 and protein S and the TAM receptor tyrosine kinases in human atherosclerotic carotid plaques. Thrombosis and Haemostasis 2011, 105:873-882.
108. Tjwa M., Moons L., Lutgens E. Pleiotropic role of growth arrest-specific gene 6 in atherosclerosis. Current Opinion in Lipidology 2009, 20:386-392.
109. Ming Cao W., Murao K., Imachi H., et al. Phosphatidylinositol 3-OH kinase-Akt/protein kinase B pathway mediates Gas6 induction of scavenger receptor a in immortalized human vascular smooth muscle cell line. Arteriosclerosis, Thrombosis and Vascular Biology 2001, 21:1592-1597.
110. Cavet M.E., Smolock E.M., Ozturk O.H., et al. Gas6-axl receptor signaling is regulated by glucose in vascular smooth muscle cells. Arteriosclerosis, Thrombosis and Vascular Biology 2008, 28:886-891.
111. Ganopolsky J.G., Abid M.R., Aird W.C., et al. GAS6-induced signaling in human endothelial cells is mediated by FOXO1a. Journal of Thrombosis and Haemostasis 2008, 6:1804-1811.
112. Tjwa M., Bellido-Martin L., Lin Y., et al. Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood 2008, 111:4096-4105.
113. Melaragno M.G., Wuthrich D.A., Poppa V., et al. Increased expression of Axl tyrosine kinase after vascular injury and regulation by G protein-coupled receptor agonists in rats. Circulation Research 1998, 83:697-704.
114. Korshunov V.A., Mohan A.M., Georger M.A., et al. Axl, a receptor tyrosine kinase, mediates flow-induced vascular remodeling. Circulation Research 2006, 98:1446-1452.
115. Konishi A., Aizawa T., Mohan A., et al. Hydrogen peroxide activates the Gas6-Axl pathway in vascular smooth muscle cells. Journal of Biological Chemistry 2004, 279:28766-28770.
116. Lutgens E., Tjwa M., Garcia de Frutos P., et al. Genetic loss of Gas6 induces plaque stability in experimental atherosclerosis. The Journal of Pathology 2008, 216:55-63.
117. Thorp E., Cui D., Schrijvers D.M., et al. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of ApoE-/- mice. Arteriosclerosis, Thrombosis and Vascular Biology 2008, 28:1421-1428.
118. Liao D., Wang X., Li M., et al. Human protein S inhibits the uptake of AcLDL and expression of SR-A through Mer receptor tyrosine kinase in human macrophages. Blood 2009, 113:165-174.
119. Zhu D., Wang Y., Singh I., et al. Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor. Blood 2010, 115:4963-4972.
120. Zhong Z., Wang Y., Guo H., et al. Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like region. The Journal of Neuroscience 2010, 30:15521-15534.
121. Zhang L., Zhang Z.G., Zhang C., et al. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model. Stroke 2004, 35:2890-2895.
122. Ding G., Jiang Q., Zhang L., et al. Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor. Journal of Cerebral Blood Flow and Metabolism 2005, 25:87-97.
123. Arundine M., Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cellular and Molecular Life Sciences 2004, 61:657-668.
124. Liu D., Cheng T., Guo H., et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nature Medicine 2004, 10:1379-1383.
125. Guo H., Barrett T.M., Zhong Z., et al. Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl d-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway. Molecular Neurodegeneration 2011, 6:13.
126. Poole T.J., Coffin J.D. Vasculogenesis and angiogenesis: two distinct morphogenetic mechanisms establish embryonic vascular pattern. The Journal of Experimental Zoology 1989, 251:224-231.
127. Saraswati S., Alfaro M.P., Thorne C.A., et al. Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling. PLoS ONE 2010, 5:e15521.
128. Fair D.S., Marlar R.A., Levin E.G. Human endothelial cells synthesize protein S. Blood 1986, 67:1168-1171.
129. Stern D., Brett J., Harris K., et al. Participation of endothelial cells in the protein C-protein S anticoagulant pathway: the synthesis and release of protein S. The Journal of Cell Biology 1986, 102:1971-1978.
130. Manfioletti G., Brancolini C., Avanzi G., et al. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Molecular and Cellular Biology 1993, 13:4976-4985.
131. Benzakour O., Kanthou C. The anticoagulant factor, protein S, is produced by cultured human vascular smooth muscle cells and its expression is up-regulated by thrombin. Blood 2000, 95:2008-2014.
132. Melaragno M.G., Fridell Y.W., Berk B.C. The Gas6/Axl system: a novel regulator of vascular cell function. Trends in Cardiovascular Medicine 1999, 9:250-253.
133. Benzakour O., Formstone C., Rahman S., et al. Evidence for a protein S receptor(s) on human vascular smooth muscle cells. Analysis of the binding characteristics and mitogenic properties of protein S on human vascular smooth muscle cells. Biochemical Journal 1995, 308(Pt 2):481-485.
134. Gasic G.P., Arenas C.P., Gasic T.B., et al. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:2317-2320.
135. Ruan G.X., Kazlauskas A. Axl is essential for VEGF-A-dependent activation of PI3K/Akt. The EMBO Journal 2012, 31:1692-1703.
136. Fraineau S., Monvoisin A., Clarhaut J., et al. The vitamin K-dependent anticoagulant factor, protein S, inhibits multiple VEGF-A-induced angiogenesis events in a Mer- and SHP2-dependent manner. Blood 2012, 120:5073-5083.
137. Nicolson G.L. Molecular mechanisms of cancer metastasis: tumor and host properties and the role of oncogenes and suppressor genes. Current Opinion in Oncology 1991, 3:75-92.
138. Coleman W.B., Tsongalis G.J. Molecular mechanisms of human carcinogenesis. Experientia 2006, 321-349.
139. Compagni A., Christofori G. Recent advances in research on multistage tumorigenesis. British Journal of Cancer 2000, 83:1-5.
140. Milsom C., Yu J., May L., et al. The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression. Thrombosis Research 2007, 120(Suppl. 2):S82-S91.
141. Boukerche H., Berthier-Vergnes O., Penn F., et al. Human melanoma differ in their capacity to release ADP and aggregate platelets. British Journal of Haematology 1994, 763:763-772.
142. Donati M.B., Falanga A. Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematologica 2001, 106:18-24.
143. Boukerche H., Berthier-Vergnes O., Tabone E., et al. Platelet-melanoma cell interaction is mediated by the glycoprotein IIb-IIIa complex. Blood 1989, 74:658-663.
144. Rak J., Yu J.L., Luyendyk J., et al. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Research 2006, 66:10643-10646.
145. Donati M.B. Thrombosis and cancer: Trousseau syndrome revisited. Best Practice and Research: Clinical Haematology 2009, 22:3-8.
146. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007, 110:1723-1729.
147. Sorensen H.T., Mellemkjaer L., Olsen J.H., et al. Prognosis of cancers associated with venous thromboembolism. The New England Journal of Medicine 2000, 343:1846-1850.
148. Lee A.Y. Anti-thrombotic therapy in cancer patients. Expert Opinion on Pharmacotherapy 2003, 4:2213-2220.
149. Lee A.Y., Levine M.N. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003, 107:I17-I21.
150. Falanga A., Marchetti M., Russo L. Venous thromboembolism in the hematologic malignancies. Current Opinion in Oncology 2012, 24:702-710.
151. Beer J.H., Haeberli A., Vogt A., et al. Coagulation markers predict survival in cancer patients. Thrombosis and Haemostasis 2002, 88:745-749.
152. Phillips D.J., Greengard J.S., Fernandez J.A., et al. Protein S: an antithrombotic factor, is synthesized and released by neural tumor cells. Journal of Neurochemistry 1993, 61:344-347.
153. Wimmel A., Rohner I., Ramaswamy A., et al. Synthesis and secretion of the anticoagulant protein S and coexpression of the Tyro3 receptor in human lung carcinoma cells. Cancer 1999, 86:43-49.
154. Wojtukiewicz M.Z., Zacharski L.R., Memoli V.A., et al. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 1990, 65:481-485.
155. Chung K.W., Kim S.W., Kim S.W. Gene expression profiling of papillary thyroid carcinomas in Korean patients by oligonucleotide microarrays. Journal of the Korean Surgical Society 2012, 82:271-280.
156. Griffith O.L., Melck A., Jones S.J., et al. Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. Journal of Clinical Oncology 2006, 24:5043-5051.
157. Wojtukiewicz M.Z., Zacharski L.R., Memoli V.A., et al. Malignant melanoma: interaction with coagulation and fibrinolysis pathways in situ. American Journal of Clinical Pathology 1990, 93:516-521.
158. Wojtukiewicz M.Z., Sierko E., Zacharski L.R., et al. Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. Seminars in Thrombosis and Hemostasis 2003, 29:291-300.
159. Wojtukiewicz M.Z., Sierko E., Zimnoch L., et al. Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thrombosis and Haemostasis 2003, 90:140-146.
160. Wojtukiewicz M.Z., Rucinska M., Zacharski L.R., et al. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thrombosis and Haemostasis 2001, 86:1416-1420.
161. Sierko E., Wojtukiewicz M.Z., Zawadzki R., et al. Expression of protein C (PC), protein S (PS) and thrombomodulin (TM) in human colorectal cancer. Thrombosis Research 2010, 125:e71-e75.
162. Saraon P., Musrap N., Cretu D., et al. Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer. The Journal of Biological Chemistry 2012, 287:34019-34031.
163. Ji M., Yoon S.N., Lee W., et al. Protein S deficiency with a PROS1 gene mutation in a patient presenting with mesenteric venous thrombosis following total colectomy. Blood Coagulation and Fibrinolysis 2011, 22:619-621.
164. Linger R.M., Cohen R.A., Cummings C.T., et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene 2012, (Epub ahead of print).
165. Brown J.E., Krodel M., Pazos M., et al. Cross-phosphorylation, signaling and proliferative functions of the Tyro3 and Axl receptors in Rat2 cells. PLoS ONE 2012, 7:e36800.
166. Linger R.M., Keating A.K., Earp H.S., et al. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opinion on Therapeutic Targets 2010, 14:1073-1090.
167. Verma A., Warner S.L., Vankayalapati H., et al. Targeting Axl and Mer kinases in cancer. Molecular Cancer Therapeutics 2011, 10:1763-1773.
168. Brandao L., Migdall-Wilson J., Eisenman K., et al. TAM receptors in leukemia: expression, signaling, and therapeutic implications. Critical Reviews in Oncogenesis 2011, 16:47-63.
169. Holland S.J., Powell M.J., Franci C., et al. Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Research 2005, 65:9294-9303.
170. Tavazoie S.F., Alarcon C., Oskarsson T., et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-152.
171. Yuen H.F., McCrudden C.M., Huang Y.H., et al. TAZ expression as a prognostic indicator in colorectal cancer. PLoS ONE 2013, 8:e54211.
172. Craven R.J., Xu L.H., Weiner T.M., et al. Receptor tyrosine kinases expressed in metastatic colon cancer. International Journal of Cancer 1995, 60:791-797.
173. El Sayadi H., Pissaloux D., Alberti L., et al. Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas. Targeted Oncology 2013, (Epub ahead of print).
174. Sawabu T., Seno H., Kawashima T., et al. Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Molecular Carcinogenesis 2007, 46:155-164.
175. Wu C.W., Li A.F., Chi C.W., et al. Clinical significance of AXL kinase family in gastric cancer. Anticancer Research 2002, 22:1071-1078.
176. He L., Zhang J., Jiang L., et al. Differential expression of Axl in hepatocellular carcinoma and correlation with tumor lymphatic metastasis. Molecular Carcinogenesis 2010, 49:882-891.
177. Tsou A.P., Wu K.M., Tsen T.Y., et al. Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics 1998, 50:331-340.
178. Wimmel A., Glitz D., Kraus A., et al. Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. European Journal of Cancer 2001, 37:2264-2274.
179. Brandao L.N., Winges A., Christoph S., et al. Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia. Blood Cancer Journal 2013, 3:e101.
180. Yeoh E.J., Ross M.E., Shurtleff S.A., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1:133-143.
181. Ek S., Hogerkorp C.M., Dictor M., et al. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Research 2002, 62:4398-4405.
182. Challier C., Uphoff C.C., Janssen J.W., et al. Differential expression of the ufo/axl oncogene in human leukemia-lymphoma cell lines. Leukemia 1996, 10:781-787.
183. Demarest S.J., Gardner J., Vendel M.C., et al. Evaluation of tyro3 expression, gas6-mediated akt phosphorylation, and the impact of anti-tyro3 antibodies in melanoma cell lines. Biochemistry 2013, 52:3102-3118.
184. Tworkoski K., Singhal G., Szpakowski S., et al. Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Molecular Cancer Research 2011, 9:801-812.
185. van Ginkel P.R., Gee R.L., Shearer R.L., et al. Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Research 2004, 64:128-134.
186. De Vos J., Couderc G., Tarte K., et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001, 98:771-780.
187. Deitcher S.R., Erban J.K., Limentani S.A. Acquired free protein S deficiency associated with multiple myeloma: a case report. American Journal of Hematology 1996, 51:319-323.
188. Crosier P.S., Hall L.R., Vitas M.R., et al. Identification of a novel receptor tyrosine kinase expressed in acute myeloid leukemic blasts. Leukemia and Lymphoma 1995, 18:443-449.
189. Lee-Sherick A.B., Eisenman K.M., Sather S., et al. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene 2013.
190. Abe A., Emi N., Kato H., et al. Establishment and characterization of an immature human megakaryoblastic cell line, MEG-A2. Leukemia 1995, 9:341-349.
191. Vajkoczy P., Knyazev P., Kunkel A., et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:5799-5804.
192. Huang H., Colella S., Kurrer M., et al. Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Research 2000, 60:6868-6874.
193. Keating A.K., Kim G.K., Jones A.E., et al. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Molecular Cancer Therapeutics 2010, 9:1298-1307.
194. Sun W., Fujimoto J., Tamaya T. Coexpression of Gas6/Axl in human ovarian cancers. Oncology 2004, 66:450-457.
195. Faca V.M., Ventura A.P., Fitzgibbon M.P., et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS ONE 2008, 3:e2425.
196. Nakano T., Tani M., Ishibashi Y., et al. Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clinical and Experimental Metastasis 2003, 20:665-674.
197. Zhang Y., Tang Y.J., Man Y., et al. Knockdown of AXL receptor tyrosine kinase in osteosarcoma cells leads to decreased proliferation and increased apoptosis. International Journal of Immunopathology and Pharmacology 2013, 26:179-188.
198. Maillard C., Berruyer M., Serre C.M., et al. Protein-S, a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblasts. Endocrinology 1992, 130:1599-1604.
199. Lowe A.W., Olsen M., Hao Y., et al. Gene expression patterns in pancreatic tumors, cells and tissues. PLoS ONE 2007, 2:e323.
200. Odegaard O.R., Lindahl A.K., Try K., et al. Recurrent venous thrombosis during warfarin treatment related to acquired protein S deficiency. Thrombosis Research 1992, 66:729-734.
201. Evans C.O., Young A.N., Brown M.R., et al. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. The Journal of Clinical Endocrinology and Metabolism 2001, 86:3097-3107.
202. Taichman R.S., Patel L.R., Bedenis R., et al. GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS ONE 2013, 8:e61873.
203. Jacob A.N., Kalapurakal J., Davidson W.R., et al. A receptor tyrosine kinase, UFO/Axl, and other genes isolated by a modified differential display PCR are overexpressed in metastatic prostatic carcinoma cell line DU145. Cancer Detection and Prevention 1999, 23:325-332.
204. Wu Y.M., Robinson D.R., Kung H.J. Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Research 2004, 64:7311-7320.
205. Gustafsson A., Bostrom A.K., Ljungberg B., et al. Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma. PLoS ONE 2009, 4:e7575.
206. Chung B.I., Malkowicz S.B., Nguyen T.B., et al. Expression of the proto-oncogene Axl in renal cell carcinoma. DNA and Cell Biology 2003, 22:533-540.
207. Bai Y., Li J., Fang B., et al. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Research 2012, 72:2501-2511.
208. Khan J., Bittner M.L., Saal L.H., et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:13264-13269.
209. Avilla E., Guarino V., Visciano C., et al. Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Research 2011, 71:1792-1804.
210. Sun W.S., Fujimoto J., Tamaya T. Coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases Axl and Sky in human uterine endometrial cancers. Annals of Oncology 2003, 14:898-906.
211. Hong C.C., Lay J.D., Huang J.S., et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Letters 2008, 268:314-324.
212. Mahadevan D., Cooke L., Riley C., et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007, 26:3909-3919.
213. Gioia R., Leroy C., Drullion C., et al. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood 2011, 118:2211-2221.
214. Huang F., Hurlburt W., Greer A., et al. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Research 2010, 70:7221-7231.
215. Liu L., Greger J., Shi H., et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Research 2009, 69:6871-6878.
216. Macleod K., Mullen P., Sewell J., et al. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Research 2005, 65:6789-6800.
217. Dufies M., Jacquel A., Belhacene N., et al. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget 2011, 2:874-885.